It appears you don't have support to open PDFs in this web browser. To view this file, Open with your PDF reader
Abstract
Huntington disease is a neurodegenerative condition for which there is no cure to date. Activation of AMP-activated protein kinase has previously been shown to be beneficial in in vitro and in vivo models of Huntington’s disease. Moreover, a recent cross-sectional study demonstrated that treatment with metformin, a well-known activator of this enzyme, is associated with better cognitive scores in patients with this disease. We performed a preclinical study using metformin to treat phenotypes of the zQ175 mouse model of Huntington disease. We evaluated behavior (motor and neuropsychiatric function) and molecular phenotypes (aggregation of mutant huntingtin, levels of brain-derived neurotrophic factor, neuronal inflammation, etc.). We also used two models of polyglutamine toxicity in Caenorhabditis elegans to further explore potential mechanisms of metformin action. Our results provide strong evidence that metformin alleviates motor and neuropsychiatric phenotypes in zQ175 mice. Moreover, metformin intake reduces the number of nuclear aggregates of mutant huntingtin in the striatum. The expression of brain-derived neurotrophic factor, which is reduced in mutant animals, is partially restored in metformin-treated mice, and glial activation in mutant mice is reduced in metformin-treated animals. In addition, using worm models of polyglutamine toxicity, we demonstrate that metformin reduces polyglutamine aggregates and restores neuronal function through mechanisms involving AMP-activated protein kinase and lysosomal function. Our data indicate that metformin alleviates the progression of the disease and further supports AMP-activated protein kinase as a druggable target against Huntington’s disease.
Huntington’s disease: Diabetes drug limits disease-related degeneration in mice
Metformin, an existing drug for diabetes, shows promise in alleviating symptoms of early Huntington’s disease in mouse models. Huntington’s disease is a genetic disorder that results in the gradual deterioration of motor skills and cognitive ability. It is caused by a defect in a single gene that then encodes a mutant huntingtin protein, which aggregates and kills brain cells. Growing observational evidence suggests that patients undergoing metformin treatment for diabetes type II exhibit fewer symptoms of age-related disease, as well as Huntington’s disease. Rafael Vázquez-Manrique at Hospital Universitario y Politécnico La Fe, València and Pascual Sanz at IBV-CSIC and CIBERER, València, and scientists across Spain used metformin to treat motor and neuropsychiatric symptoms in a Huntington’s mouse model. They found that metformin alleviated symptoms by actively reducing huntingtin levels, dispersing aggregations and limiting brain inflammation.
You have requested "on-the-fly" machine translation of selected content from our databases. This functionality is provided solely for your convenience and is in no way intended to replace human translation. Show full disclaimer
Neither ProQuest nor its licensors make any representations or warranties with respect to the translations. The translations are automatically generated "AS IS" and "AS AVAILABLE" and are not retained in our systems. PROQUEST AND ITS LICENSORS SPECIFICALLY DISCLAIM ANY AND ALL EXPRESS OR IMPLIED WARRANTIES, INCLUDING WITHOUT LIMITATION, ANY WARRANTIES FOR AVAILABILITY, ACCURACY, TIMELINESS, COMPLETENESS, NON-INFRINGMENT, MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE. Your use of the translations is subject to all use restrictions contained in your Electronic Products License Agreement and by using the translation functionality you agree to forgo any and all claims against ProQuest or its licensors for your use of the translation functionality and any output derived there from. Hide full disclaimer
Details


1 Health Research Institute La Fe (Hospital Universitario y Politécnico La Fe), Research Group in Molecular, Cellular and Genomic Biomedicine, València, Spain (GRID:grid.84393.35) (ISNI:0000 0001 0360 9602)
2 Universitat Politécnica de València, Department of Biotechnology, Escuela Técnica Superior de Ingeniería Agronómica y del Medio Natural (ETSIAMN), València, Spain (GRID:grid.157927.f) (ISNI:0000 0004 1770 5832)
3 Health Research Institute La Fe (Hospital Universitario y Politécnico La Fe), Statistics Unit, València, Spain (GRID:grid.84393.35) (ISNI:0000 0001 0360 9602)
4 Health Research Institute La Fe (Hospital Universitario y Politécnico La Fe), Research Group in Molecular, Cellular and Genomic Biomedicine, València, Spain (GRID:grid.84393.35) (ISNI:0000 0001 0360 9602); CIBER de Enfermedades Raras (CIBERER), Madrid, Spain (GRID:grid.452372.5) (ISNI:0000 0004 1791 1185)
5 CIBER de Enfermedades Raras (CIBERER), Madrid, Spain (GRID:grid.452372.5) (ISNI:0000 0004 1791 1185); CSIC, Instituto de Biomedicina de València, València, Spain (GRID:grid.4711.3) (ISNI:0000 0001 2183 4846)